McKesson shares are trading lower despite reporting better-than-expected Q2 financial results and raising FY26 adjusted EPS guidance with its midpoint above estimates. The company's FY26 sales guidance midpoint is slightly above estimates, and management noted lower branded pharmaceutical pricing on its conference call.

McKesson Buys Precision Medicine to Expand Clinical Research and Commercialization

McKesson will acquire Precision Medicine Group for $2.25 billion, expanding its clinical research and drug commercialization services.

McKesson To Acquire Precision Medicine Group For ~$2.25

Barclays Maintains Overweight on McKesson, Raises Price Target to $1000

Barclays analyst Glen Santangelo maintains McKesson (NYSE:MCK) with a Overweight and raises the price target from $925 to $1000.

RBC Capital Initiates Coverage On McKesson with Sector Perform Rating, Announces Price Target of $845

RBC Capital analyst Ryan Halsted initiates coverage on McKesson (NYSE:MCK) with a Sector Perform rating and announces Price Target of $845.